CGON
CG Oncology, Inc. Common stock
NASDAQ · Healthcare · Biotechnology · US
$74.67
+0.46%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.86
- Revenue estimate
- $547.7K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.90
- EPS estimate
- -$0.66
- Revenue actual
- $1.2M
- Revenue estimate
- $360.8K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -17.5%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $83
- PT range
- $79 – $85
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026